Korea’s Celltrion issues $300 million CB

The deal is well-received, particularly by outright investors who see good growth potential for the Kosdaq-listed developer of biologic drugs.
<div style="text-align: left;">
Korea Exchange
</div>
<div style="text-align: left;"> Korea Exchange </div>

Korean biopharmaceutical company Celltrion last night raised $300 million from a convertible bond to fund product development, raw materials costs and other working capital requirements. The company, which is listed on Kosdaq, doesn’t have any outstanding debt in the international markets and this was its debut CB.

The deal has a five-year maturity but can be put back to the company at par on the third anniversary. Like other Korean CBs it has a delayed conversion period, but instead of the 12-month delay that is required by regulators, the Celltrion CB cannot be converted until 18 months into the life of the bond.

A source noted...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222